Lexaria Bioscience Management
Management criteria checks 2/4
Lexaria Bioscience's CEO is Rich Christopher, appointed in Aug 2024, has a tenure of 1.42 years. total yearly compensation is $612.52K, comprised of 75.2% salary and 24.8% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $50.83K. The average tenure of the management team and the board of directors is 1.3 years and 3 years respectively.
Key information
Rich Christopher
Chief executive officer
US$612.5k
Total compensation
| CEO salary percentage | 75.23% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Nov 30 2025 | n/a | n/a | -US$11m |
| Aug 31 2025 | US$613k | US$461k | -US$12m |
| May 31 2025 | n/a | n/a | -US$11m |
| Feb 28 2025 | n/a | n/a | -US$9m |
| Nov 30 2024 | n/a | n/a | -US$7m |
| Aug 31 2024 | US$519k | n/a | -US$6m |
Compensation vs Market: Rich's total compensation ($USD612.52K) is about average for companies of similar size in the US market ($USD572.27K).
Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.
CEO
Rich Christopher (55 yo)
Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024 and serves as its Director since January 14, 2025. He served as Chief Financial O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$612.52k | 0.26% $ 50.8k | |
| Chairman of the Scientific Advisory Board | 10.8yrs | US$523.50k | 0.022% $ 4.2k | |
| Chief Financial Officer | 1.3yrs | US$248.39k | 0.060% $ 11.7k | |
| Director of Operations | no data | no data | no data | |
| Head of Legal | no data | no data | 0.0030% $ 585.8 | |
| Chief Medical Advisor & Member of Scientific Advisory Board | 1.1yrs | no data | no data |
Experienced Management: LEXX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1yr | US$612.52k | 0.26% $ 50.8k | |
| Chairman of the Scientific Advisory Board | 9.8yrs | US$523.50k | 0.022% $ 4.2k | |
| Chief Medical Advisor & Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Independent Director | 5yrs | US$59.32k | 0.044% $ 8.5k | |
| Chairman of the Board | 19.3yrs | US$376.42k | 1.1% $ 213.9k | |
| Independent Director | 14.5yrs | US$59.32k | 0.044% $ 8.6k | |
| Independent Director | 10.3yrs | US$53.95k | 0.073% $ 14.2k | |
| Independent Director | 1yr | US$41.20k | 0.052% $ 10.2k | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data |
Experienced Board: LEXX's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 22:26 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/11/30 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexaria Bioscience Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Michael Okunewitch | Maxim Group |